Sitoiganap, an advanced immunotherapy by ERC, is now authorized and fully reimbursed in Kosovo. Pharmabel coordinates the complete care pathway for international patients.
Pharmabel is a pharmaceutical company based in Pristina, Kosovo.
We operate at the intersection of two missions: making breakthrough treatments accessible to patients who need them starting with Sitoiganap, the first authorized immunotherapy for Glioblastoma Multiforme and building the next generation of pharmaceutical production infrastructure.
What we do
We don't just distribute treatments. We build the systems, the partnerships, and the pathways that turn medical innovation into patient access.
For the first time, an immunotherapy for Glioblastoma Multiforme has received full governmental authorization — with standard public reimbursement, no restrictions, no exceptional conditions.
In partnership with ERC, Pharmabel provides international patients with a fully managed care program in Pristina: medical team, accommodation, transport, interpreters, and 24/7 support.
Everything is taken care of, so patients and their families can focus on what matters.
